Global Freight and Logistics Expert Brings Over 30 Years of Industry Leadership Experience Freightos Limited (NASDAQ: CRGO), the leading vendor-neutral global freight booking and payment platform, today announced the appointment of Michael Schaecher to its Board of Directors, effective October 19, 2025. This strategic addition further expands the Board's depth of expertise in air and […]
(NYSE:WGO), — Favorable Product Mix and Targeted Price Increases Drive Solid Top-Line Growth in Q4 — — Efficiency Actions Contributed to Q4 Operating Cash Flow of $181.4 Million — — Balance Sheet Strength Fortified as Leverage Ratio Improves — — Barletta Continues Share Expansion in U.S. Aluminum Pontoon Segment(1) — — Grand Design RV and
NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) — ATLAS SP Partners (“ATLAS”), the warehouse finance and securitized products business majority owned by Apollo funds, today announced the recapitalization of Atlas Warehouse Lending Company, L.P. (“AWLC”). AWLC is a wholly owned, investment-grade-rated subsidiary of WHCO Intermediate Holdings L.P. (“Atlas Warehouse Company”), which serves as the primary
Pretzl launches with a proprietary AI-driven platform, JourneyLab, to help brands better understand and manage the increasingly complex B2B buyers' journey Today, five longstanding B2B agencies within the Next 15 Group, announce they will combine into one new business: Pretzl. The new B2B marketing business, Pretzl, will fully come to market in February 2026, bringing
ELA026 has demonstrated promising potential as a frontline treatment for patients with sHLH, a hyperinflammatory disease with high mortality and significant unmet medical need Electra has initiated the SURPASS global pivotal trial evaluating ELA026 in patients with sHLH SOUTH SAN FRANCISCO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) — Electra Therapeutics, a clinical stage biotechnology company
Proceeds will fund a global pivotal trial of lead product candidate, ELA026, as a frontline treatment for secondary hemophagocytic lymphohistiocytosis (sHLH) Financing will also support indication expansion of ELA026 in hematologic cancers and advance second pipeline program, ELA822, into the clinic for diseases in immunology and inflammation (I&I) Financing co-led by Nextech and EQT Life
The SURPASS study is enrolling patients at research sites across the U.S. and Europe ELA026 targets signal regulatory proteins (SIRP) as a novel approach to treating the life-threatening hyperinflammatory pathology of sHLH SOUTH SAN FRANCISCO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) — Electra Therapeutics, a clinical stage biotechnology company pioneering therapies against novel targets for
(NYSE:SF), ST. LOUIS, Mo., Oct. 22, 2025 (GLOBE NEWSWIRE) — Stifel Financial Corp. (NYSE: SF) today reported net revenues of $1.4 billion for the three months ended September 30, 2025, compared with $1.2 billion a year ago. Net income available to common shareholders was $202.1 million, or $1.84 per diluted common share, compared with $149.2
(TSX:TLG),(OTC US:CHXMF),(Other OTC:CHXMF),(Boerse Frankfurt – Freiverkehr:CM5R), MONTREAL, Oct. 22, 2025 (GLOBE NEWSWIRE) — Troilus Gold Corp. (TSX: TLG; OTCQX: CHXMF; FSE: CM5R) (“Troilus” or the “Company”) announces that it has changed its auditor from McGovern Hurley LLP (“Former Auditor”) to Deloitte LLP (“Successor Auditor” or “Deloitte LLP”) effective October 21, 2025. The appointment of Deloitte
QuidelOrtho Corporation (Nasdaq: QDEL)(the “Company” or “QuidelOrtho”), a global leader of in vitro diagnostics, announced today that it will report its financial results for the third quarter 2025 ended September 28, 2025, after the market closes on Wednesday, November 5, 2025. https://mma.prnewswire.com/media/2724032/QuidelOrtho_Corporation_Logo.jpg Following the release of financial results, QuidelOrtho will hold a conference call beginning